Hospital-Acquired Infections (HAIs) are a leading cause of death throughout the world. Hands are often infection vectors for the microbes that cause illness. The potential to spread deadly pathogens through cross-contamination is increasing as the advent of electronic medical records requires greater use of shared workstations. Computer keyboards and mice are two of the top five fomites for cross-contamination.

Preventing deadly diseases such as methicillin-resistant staphylococcus aureus (MRSA), Clostridium difficile (C. difficile) and norovirus is a top priority for hospitals. However, many organizations struggle with the challenge of manually disinfecting shared surfaces in busy environments. Frequent hand washing and other existing interventions are time-consuming and break down due to lack of human compliance.

The Vioguard Defender is a self-sanitizing keyboard and track pad system. It is FDA cleared and uses the germicidal properties of ultraviolet light (UV-C) to automatically disinfect after every use. The system is 99.99% effective in killing harmful microorganisms within seconds, eliminating the need for manual cleaning. The Defender does not require human intervention. The sanitization process engages automatically and confirms the surfaces have been properly sanitized, ensuring consistent and reliable disinfection.

More than clean. SANITIZED. FDA CLEARED.
Since the early 20th century, ultraviolet germicidal irradiation has been used as an effective disinfectant in HVAC, water treatment facilities and hospital environments. Hospital-borne pathogens can be killed or rendered harmless with the use of UV-C in appropriate dosages by effectively disrupting microorganisms’ DNA and RNA while preventing colonization.

Unlike their resilient response to chemical disinfectants, microorganisms are unable to develop UV-C resistance. Widespread use of antibiotics and disinfectants continue to create chemical and drug-resistant “superbugs,” which the CDC lists as a top threat for 2017. The Vioguard solution kills these superbugs and will not create new, resistant microorganisms.

The Centers for Disease Control (CDC) estimates that 4 percent of hospital patients acquire an infection in the U.S.,2 which results in $35-45 billion in direct medical costs each year.3

Vioguard is committed to developing products that enhance the effectiveness of infection control strategies without compromising productivity or accuracy. The robust patent portfolio secures Vioguard’s market footprint with 11 patents, two patents pending and one provisional patent. It has passed rigorous FDA test protocol conducted by third-party labs.